Deals In Depth: February 2020
Executive Summary
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
You may also be interested in...
Seven Key Success Factors In Market Opportunity Assessments
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Solutions Exist To Regenerative Medicine's Most Pressing Manufacturing Challenges
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021
Coming year could feature first-time approvals in the EU for at least five gene therapies.